tbuckley/cabot-search huggingface dataset:
ATIM-10. CLINICAL PREDICTORS OF RESPONSE FOR RECURRENT/REFRACTORY GLIOBLASTOMA MULTIFORME (GBM) AND ANAPLASTIC ASTROCYTOMA (AA, WHO GRADE III) PATIENTS TREATED WITH THE ANTI-TGFß2 RNA THERAPEUTIC OT-101
Authors: Sanjive Qazi, David Nam, Larn Hwang, Vuong Trieu, Fatih Uckun
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND OT-101 is a first-in-class αTGF-ß2 RNA therapeutic and exhibits significant single-agent activity in patients with recurrent/refractory (R/R) GBM and AA. Here we report significant predictors of best overall response (BOR = CR, PR, stable disease &gt;6 months) and improved OS for R/R GBM and AA patients after treatment with OT-101 on the Phase II study NCT00431561. METHODS A generalized linear model (GLM; Binomial distribution, logit function link function) was fitted to explore several clinical parameters as potential predictors for BOR. The parametric survival model fitted the time to death using linear regression to predict improved OS. The best fit model was chosen utilizing both Akaike information criterion (AIC) and Bayesian information criterion (BIC) from assessing Weibull, lognormal, exponential, Fréchet, and loglogistic distributions of the survival probabilities (JMP 10.02, SAS, Cary NC). RESULTS In both models, time from last chemo-/radiation therapy, time from first diagnosis and baseline hematological measurements (ALC, ANC and WBC) were removed from the model as they lacked significant predictive value. The final GLM (chi-square value = 39.7, df = 12, P&lt; 0.0001) and OS (chi-square value = 56.0, df = 12, P&lt; 0.0001) models contained 7 predictor variables measured in 67 evaluable patients: Baseline Karnofsky performance scale (KPS) score; composition of previous therapy; cancer subtype; steroid use; total OT-101 dose; age; and baseline 3D tumor volume for the target lesion. Three significant predictors were identified: Baseline KPS score (P[BOR] = 0.011; P[OS] = 0.0004), cancer subtype (P[BOR] = 0.017, P[OS] = 0.036) and steroid use (P[BOR] = 0.0067, P[OS] = 0.0022). CONCLUSION Being an AA patient rather than a GBM patient, having a higher baseline KPS score, receiving either no steroids or short-term steroids during management of AE are associated with BOR and improved OS for R/R GBM/AA patients treated with OT-101 as a single agent.
Defining drug‐free remission of skin disease in patients with plaque psoriasis
Authors: A.W. Armstrong, A. Blauvelt, J.J. Crowley, K.B. Gordon, G.G. Krueger, J.G. Krueger, J.M. Sobell, B.E. Strober, B. Srivastava, A. Menter
Journal: British Journal of Dermatology (2019)
Pediatric Emergency Department Use of Intranasal Fentanyl to Treat Pain in Children with Sickel Cell Disease and Its Impact on Discharge Rates: A Multicenter Perspective
Authors: Claudia R. Morris, Fahd Ahmad, Jonathan Bennett, Seema Bhatt, Amanda Bogie, Kathleen M Brown, T.Charles Casper, Laura L. Chapman, Corrie E. Chumpitazi, Daniel M. Cohen, Carlton Dampier, Angela M. Ellison, Hartmut Grasemann, Robert W. Hickey, Lewis L. Hsu, Peter A. Lane, Sara Leibovich, Prahbumallikarjum Patil, Elizabeth C. Powell, Rachel Richards, Syana Sarnaik, Debra L. Weiner, David C. Brousseau
Journal: Blood (2016)
Bullous Lesions in Acute Barbiturate Intoxication
Authors: G. Warnock
Journal: BMJ (1965)

MEDITALSOUHALneedle was used and the dorsum of the hand always chosen as the site of injection.With a little care this can be a relatively easy tech- nique.The results were much improved.The local anaesthetic used was prilocaine (Citanest) 0.5% without adrenaline, the aver- age dose being 30 ml. (150 mg.), decreasing to 20 ml.(100 mg.) in thin and frail limbs and increasing to 40 ml.(200 mg.) in fat and more muscular limbs.In one case a total of 60 ml.(300 mg.) had to be injected as the tourniquet accidentally deflated lN minutes after the first 40 ml.had been injected.There were no systemic effects seen in any case.The time of inflation of the tourniquet ranged from 10 minutes to 1 hour 45 minutes.-Iam, etc.,
Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab
Authors: Stephen D. Smith, Javier Munoz, Don Stevens, Sonali M. Smith, Tatyana A. Feldman, J Christine Ye, Sven de Vos, Brian T. Hess, Carole B. Miller, James L. Khatcheressian, Matt R. Birrell, Janet M. Leeds, Gregory P. Coffey, Pamela B. Conley, Glenn C. Michelson, John T. Curnutte, Paul A. Hamlin
Journal: Blood (2019)
EXTH-49. THERAPEUTIC EFFICACY OF ENGINEERED, HYDROGEL ENCAPSULATED BIMODAL MSC IN GLIOBLASTOMA STRATIFIED ON CELL SURFACE RECEPTOR EXPRESSION
Authors: Deepak Bhere, Sung Hugh Choi, Pim van de Donk, Jasneet Khalsa, David Hope, Kiki Gortzak, Amina Kunnummal, Clemens Reinshagen, Huan Ling, Neil Vasdev, Walid Ibn Essayed, Alexandra Golby, Wenya Bi, Alarice Lowe, Hiroaki Wakimoto, Esther Revai Lechtich, Khalid Shah
Journal: Neuro-Oncology (2019)

Abstract Engineered stem cell therapeutics present a promising therapeutic strategy for glioblastoma (GBM). However, their clinical translation in GBM patients is limited due to lack of mouse models that mimic clinical GBM scenario, dearth of stratification techniques for target cohorts and safety concerns. In this study, we have validated the potential of stratifying therapy responders based on a circulating tumor cell screen and developed a unique “off-the-shelf” cell surface receptor targeted engineered bi-functional mesenchymal stem cell (MSC) for resected GBMs. We created a dual promoter self-inactivating lentiviral vector plasmid encoding death receptor (DR4/5) ligand (DRL), the tumor specific therapeutic agent and the prodrug-converting enzyme, herpes simplex virus-thymidine kinase (HSV-TK) and engineered clinical grade human bone marrow derived MSC to express the bi-modal therapeutic. We show that hyaluronic acid (HA) hydrogel encapsulated bimodal MSC are retained in the tumor resection cavity and have significant therapeutic efficacy in vitro and in vivo in mice bearing patient derived GBM tumors following DR4/5 stratification by circulating tumor cells in the blood and GBM surgical resection. We also show that fate of engineered MSC can be tracked by PET imaging and activation of pro-drug, HSV-TK enhances the therapeutic efficacy of MSC and results in their elimination post-tumor treatment. Our study reveals that local delivery of hydrogel encapsulated engineered MSC has therapeutic benefits; circumvents concerns of bio-distribution, increases on-site retention and permits tumor-selective migration. Based on this data, we are preparing for a first-in-human study of a hydrogel encapsulated engineered allogeneic MSC product, in primary GBM patients.
Monitoring of Recombinant Activated Coagulation Factor VII (rFVIIa) Therapy in Patients (pts) with Inherited Factor VII (FVII) Deficiency
Authors: Gennadii M. Galstian, Olesya A. Polevodova, Elena Yakovleva, Antonina Shchekina, Igor Davydkin, Dmitriy Kudlay
Journal: Blood (2019)
TMIC-50. 3D QUANTIFICATION OF DYNAMIC CYTOKINE GRADIENTS PRODUCED BY PRIMARY TUMOR MODELS
Authors: Eric McGhee, Juan Uruena, Alex McGhee, Duane Mitchell, Catherine Flores, W Gregory Sawyer
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND &amp; SIGNIFICANCE The immune response is a coordinated effort directed by cytokine gradients and concentrations. High sensitivity and spatial resolution are necessary to resolve cytokine gradients in 3-dimensions. This system uses in situ confocal fluorescent microscopy with printed bead-based immunoassays. The combination of 3D printing of the beads and biofabrication of patient derived tumors allows for direct imaging, quantification, and movies of tumor cytokine secretion in response to challenges from immune cells, tumor associated fibroblasts, and chemotherapeutic agents. HYPOTHESIS: Cytokine dynamics can be measured in real-time by balancing concentrations of detection antibodies in solution with stationary immunoassay beads with measured capture and release rates. Favorable balancing of assay kinetics can facilitate measurements of concentrations of cytokines between 50 pg/mL to over 2,000 pg/mL. METHODS In situ confocal fluorescent microscopy identifies position, fluorescence, and type of bead relative to the in vitro tumor. Cytokines including IL2, IL6, IL8, IL11, and IFNg and growth factors such as VEGF and TGFb have been measured for a wide range of solid tumors (brain, sarcoma, and epithelial) under different stresses. RESULTS Dynamic gradients of IL8 were found across multiple tumor models showing local concentrations in excess of 2,000 pg/mL. Production rates were estimated to be over 1 protein per second for each cell, and inclusion of cancer associated support cells showed 10x increases in some cytokines. CD4+ cell production of IL2 was confirmed and quantified and showed strong sensitivity to tumor activity and antigen presentation. Multiplexed beads of CCL2, CCL5, CXCL8, CXCL9, and CXCL10 allow for simultaneous measurement of multiple chemokines. Uncertainties associated with fluorescence measurement and quantification of concentrations will be discussed. CONCLUSIONS This integrated system of 3D assay printing, biofabrication of tumors and immune cell constructs, and in situ confocal microscopy provides the first direct measurements of 3D cytokine gradients in response to tumor stress.
ATIM-23. PRELIMINARY FINDINGS OF A PHASE I SAFETY AND BIOIMAGING TRIAL OF KB004 (IFABOTUZUMAB) IN PATIENTS WITH GLIOBLASTOMA
Authors: Hui Gan, Lawrence Cher, Po Inglis, Zarnie Lwin, Eddie Lau, Uwe Ackermann, Nicole Coombs, Kirsten Remen, Nancy Guo, Sze Ting Lee, Sylvia Gong, Jodie Palmer, Kunthi Pathmaraj, Graeme O’Keefe, Fiona Scott, Bryan Day, Andrew Boyd, Paul Thomas, Cameron Durrant, Andrew Scott
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) is the most frequent and lethal primary brain neoplasm. EphA3 is a tumor restricted antigen expressed in 38–40% of GBM and 100% of the tumor vasculature. Ifabotuzumab is a non-fucosylated IgG1κ antibody targeting EphA3 receptor. A Phase 1 study of ifabotuzumab in haematological malignancies was well tolerated and clinically active. Here we report on a Phase I dose escalation and biodistribution study of ifabotuzumab in recurrent glioblastoma. DESIGN The primary objective is to determine the toxicity and recommended phase II dose of Ifabotuzumab in GBM patients (pts). Secondary objectives are to determine the biodistribution and pharmacokinetics (PK) of 89Zr-Ifabotuzumab, the frequency of EphA3 positive GBM and response rates. Eligible pts received a trace (5mg) dose of zirconium-89 labelled ifabotuzumab (89Zr-ifab) on day 1 followed by sequential PET imaging over 1 week to determine its biodistribution, frequency of in situ EphA3 expression and tumor uptake. Safety and PK assessments were undertaken. On Day 8, pts commenced weekly ifabotuzumab infusions until PD. Three cohorts are planned (3.5mg/kg, 5.25 mg/kg, 7.9 mg/kg). On day 36, pts received both 89Zr-ifab and Ifabotuzumab, to assess receptor occupancy. Response rate (RANO) and survival data were collected. RESULTS: To date, 7 of 12 pts have enrolled (6 at 3.5 mg/kg,1 at 5.25 mg/kg; Mean age: 55 years (±12.6), 4 are male). Treatment emergent AEs included infusion reactions, seizures, cerebral oedema, rash, pruritis, headaches, eye disorder. Most were considered related to study drug, seizures and infusion reactions were readily managed with increased premedications after the first occurrence. Best response in cohort 1 is SD for 23 weeks. 89Zr-ifab PET/CT scans showed rapid, specific targeting at all known tumor sites and in all pts, but no normal tissue uptake. MRI scans showed predominant T2/FLAIR changes, occasionally marked, which were consistent with treatment effect on tumor vasculature.
An invited commentary on “Postoperative outcomes in elderly patients undergoing pancreatic resection for pancreatic adenocarcinoma: A systematic review and meta-analysis” (Int J Surg 2019 Sep 30. pii: S1743-9191(19)30262-6. doi: 10.1016/j.ijsu.2019.09.030. [Epub ahead of print])
Authors: Omeed Moaven
Journal: International Journal of Surgery (2019)
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
Authors: Lina Driouk, Joanina Gicobi, Yusuke Kamihara, Kayleigh Rutherford, Glenn Dranoff, Jerome Ritz, Susanne H.C. Baumeister
Journal: Blood (2019)
A Lipid Peroxidation Product, 4-Hydroxy-2-Nonenal, Triggers Intravascular Coagulation and Inflammation through Generation of Tissue Factor-Positive Microvesicles
Authors: Shabbir Ansari, Shiva Keshava Gaddam Bala Krishna, Usha R. Pendurthi, L. Vijaya Mohan Rao
Journal: Blood (2019)
Consensus on the key characteristics of endocrine-disrupting chemicals as a basis for hazard identification
Authors: Michele A. La Merrill, Laura N. Vandenberg, Martyn T. Smith, William Goodson, Patience Browne, Heather B. Patisaul, Kathryn Z. Guyton, Andreas Kortenkamp, Vincent J. Cogliano, Tracey J. Woodruff, Linda Rieswijk, Hideko Sone, Kenneth S. Korach, Andrea C. Gore, Lauren Zeise, R. Thomas Zoeller
Journal: Nature Reviews Endocrinology (2019)

Abstract Endocrine-disrupting chemicals (EDCs) are exogenous chemicals that interfere with hormone action, thereby increasing the risk of adverse health outcomes, including cancer, reproductive impairment, cognitive deficits and obesity. A complex literature of mechanistic studies provides evidence on the hazards of EDC exposure, yet there is no widely accepted systematic method to integrate these data to help identify EDC hazards. Inspired by work to improve hazard identification of carcinogens using key characteristics (KCs), we have developed ten KCs of EDCs based on our knowledge of hormone actions and EDC effects. In this Expert Consensus Statement, we describe the logic by which these KCs are identified and the assays that could be used to assess several of these KCs. We reflect on how these ten KCs can be used to identify, organize and utilize mechanistic data when evaluating chemicals as EDCs, and we use diethylstilbestrol, bisphenol A and perchlorate as examples to illustrate this approach.
Dynamic Easix Scores Closely Predict Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation
Authors: Mariam T. Nawas, Miriam Sanchez-Escamilla, Sean M. Devlin, Molly A. Maloy, Sergio A Giralt, Miguel-Angel Perales, Michael Scordo
Journal: Blood (2019)
Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without <i>MYCN</i> amplification
Authors: Zhi‐Xia Yue, Tian‐Yu Xing, Chao Gao, Shu‐Guang Liu, Wen Zhao, Qian Zhao, Xi‐Si Wang, Mei Jin, Xiao‐Li Ma
Journal: Cancer Communications (2019)

Abstract Background Interphase fluorescence in situ hybridization (FISH) of bone marrow cells has been confirmed to be a direct and valid method to assess the v‐myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog ( MYCN ) amplification in patients with bone marrow metastatic neuroblastoma. MYCN amplification alone, however, is insufficient for pretreatment risk stratification. Chromosome band 11q23 deletion has recently been included in the risk stratification of neuroblastoma. In the present study, we aimed to evaluate the biological characteristics and prognostic impact of 11q23 deletion and MYCN amplification in patients with bone marrow metastatic neuroblastoma. Methods We analyzed the MYCN and 11q23 statuses of 101 patients with bone marrow metastatic neuroblastoma using interphase FISH of bone marrow cells. We specifically compared the biological characteristics and prognostic impact of both aberrations. Results MYCN amplification and 11q23 deletion were seen in 12 (11.9%) and 40 (39.6%) patients. The two markers were mutually exclusive. MYCN amplification occurred mainly in patients with high lactate dehydrogenase (LDH) and high neuron‐specific enolase (NSE) levels (both P &lt; 0.001), and MYCN ‐amplified patients had more events (tumor relapse, progression, or death) than MYCN ‐normal patients ( P = 0.004). 11q23 deletion was associated only with age ( P = 0.001). Patients with MYCN amplification had poorer outcomes than those with normal MYCN (3‐year event‐free survival [EFS] rate: 8.3 ± 8.0% vs. 43.8 ± 8.5%, P &lt; 0.001; 3‐year overall survival [OS] rate: 10.4 ± 9.7% vs. 63.5% ± 5.7%, P &lt; 0.001). 11q23 deletion reflected a poor prognosis only for patients with normal MYCN (3‐year EFS rate: 34.3 ± 9.5% vs. 53.4 ± 10.3%, P = 0.037; 3‐year OS rate: 42.9 ± 10.4% vs. 75.9 ± 6.1%, P = 0.048). Those with both MYCN amplification and 11q23 deletion had the worst outcome ( P &lt; 0.001). Conclusions Chromosome band 11q23 deletion predicts poor prognosis only in bone marrow metastatic neuroblastoma patients without MYCN amplification. Combined assessment of the two markers was much superior to single‐marker assessment in recognizing the patients at a high risk of disease progression.
A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs)
Authors: D.H. Enrico, L. Lacroix, E. Rouleau, J-Y Scoazec, Y. Loriot, L. Tselikas, C. Jovelet, D. Planchard, A. Gazzah, L. Mezquita, M. Ngo, S. Michiels, A. Maillard, C. Massard, F. Facchinetti, J-C Soria, F. André, G. Vassal, L. Friboulet, B. Besse
Journal: Annals of Oncology (2019)
Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma
Authors: Kenta Mukaihara, Mattia D'Agostino, Cristina Panaroni, Keertik Fulzele, Tomoaki Mori, Ka Tat Siu, Shrikanta Chattopadhyay, Noopur Raje
Journal: Blood (2019)
A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy
Authors: Maria R Vazquez, Hagop M. Kantarjian, Gautam M. Borthakur, Susan O'Brien, Srdan Verstovsek, Farhad Ravandi, Alessandra Ferrajoli, Jorge E. Cortes, Tapan M. Kadia, William G. Wierda, Guillermo Garcia-Manero, Sara E Dellasala, Kathleen A Kehr, Sherry A. Pierce, Mary B. Rios, Elias Jabbour
Journal: Blood (2019)
Diagnosis of Lung Complication in Allogeneic Stem Cell Transplantation By Combined Use of Multiple Methods through Bronchoscopic Alveolar Lavage
Authors: Su Li, Xianmin Song, Liping Wan, Chun Wang, Yin Tong, Chongmei Huang, Xiaoqian Xu, Yu CAI, Guogang Xie, Rong Tang, Yi Sun, Aihua Bao, Jun Yang
Journal: Blood (2019)
High Dimensional Immune Profiling in Smoldering Multiple Myeloma Identifies Novel Organizing Features of the Tumor Microenvironment
Authors: Hearn Jay Cho, Deepak Perumal, Adeeb H Rahman, Seunghee Kim-Schultze, Jennifer Yesil, Daniel Auclair, Tineke Casneuf, Homer Adams, Samir Parekh, Sacha Gnjatic, Nicolas Fernandez
Journal: Blood (2019)
RARE-41. GLIOBLASTOMA MULTIFORME AND OTHER CNS TUMORS IN HEREDITARY MISMATCH REPAIR DEFICIENCIES
Authors: Evan Dishion, Clayton Korson, Darren Groh
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Lynch syndrome (LS) and constitutional mismatch repair deficiency syndrome (CMMRD) are caused by germline mutations in mismatch repair (MMR) genes, namely MLH1, MSH2, MSH6, and PMS2. LS patients have an inherited mono-allelic MMR defect, whereas CMMRD patients have a bi-allelic defect. MMR is critical to maintaining genomic integrity during DNA replication and these germline defects are known to produce microsatellite instability (MSI). Both LS and CMMRD have reported cases of increased primary brain cancer, namely glioblastoma multiforme (GBM). Given the shared pathophysiology of these syndromes, the large number of cases and registry studies published, and recent treatments of CNS tumors in CMMRD, a literature review has been conducted. OBJECTIVES: Review the pathophysiology of germline MMR deficiency and how it relates to brain tumor formation. Review the risk of developing primary CNS tumors with various MMR defects. Review the current management of CNS tumors in LS and CMMRD. METHODS Literature review of the most recent understanding of pathophysiology, all literature on CNS tumors in LS and CMMRD, and the current management of GBM including recent literature on CMMRD. RESULTS The lifetime risk of developing a primary malignant brain tumor or other CNS tumor in the United States has been calculated at 0.62%. Based on registry data, current estimates of the lifetime risk of developing a primary CNS tumor in LS is between 1–8.7%. Of the 146 genetically confirmed cases of CMMRD, 58 cases of high-grade gliomas were identified (including GBM). Most patients with CMMRD carry homozygous germline mutations in PMS2 (approximately 60%). Although primary CNS tumors appears to be a less common extra-colonic manifestation in LS, it is relatively common amongst CMMRD patients. Acknowledgement: Henry Lynch
Contributions to Global Hematology from Low and Middle-Income Countries: Insights from ASH 2018
Authors: Andrés Gómez-De León, Perla R. Colunga Pedraza, Luz del Carmen Tarín Arzaga, Emmanuel Bugarin-Estrada, David Gómez-De León, Lillian Sung, David Gomez-Almaguer
Journal: Blood (2019)
Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy
Authors: Moritz Fürstenau, Georg Hopfinger, Sandra Robrecht, Anna-Maria Fink, Othman Al-Sawaf, Petra Langerbeins, Paula Cramer, Julia Von Tresckow, Christian Maurer, Nadine Kutsch, Manuela Hoechstetter, Martin Dreyling, Elisabeth Lange, Michael Kneba, Stephan Stilgenbauer, Hartmut Döhner, Manfred Hensel, Michael G. Kiehl, Ulrich Jaeger, Clemens-Martin Wendtner, Valentin Goede, Kirsten Fischer, Michael von Bergwelt-Baildon, Barbara Eichhorst, Michael Hallek, Sebastian Theurich
Journal: Leukemia (2019)
Changing Trends in the Risk Factors of Secondary Primary Malignancies after Autologous Stem Cell Transplantation for Multiple Myeloma before and after the Introduction of Proteasome Inhibitors/Immunomodulatory Agents
Authors: Hiroyuki Takamatsu, Shohei Mizuno, Tsutomu Takahashi, Shin-Ichi Fuchida, Ichiro Hanamura, Fumihiko Nakamura, Takehiko Mori, Yuta Katayama, Noriko Doki, Nobuhiro Tsukada, Tatsuo Ichinohe, Yoshinobu Kanda, Yoshiko Atsuta, Kazutaka Sunami
Journal: Blood (2019)
Interferon Gamma, a Link between Hemophagocytic Lymphohistiocytosis and Dengue Fever Virus: A Literature Review of a Shared Inflammatory Pathway Resulting in Cytopenias and Potential Future Treatment Directions
Authors: Darla K Liles, Heather Brody, Juan Alvarez Posada, Karim Hebishi, John Thiele
Journal: Blood (2019)
Cardioprotection of Ischemia/Reperfusion Injury by Cholesterol-Dependent MG53-Mediated Membrane Repair
Authors: XianhuaWang, WenjunXie, YiZhang, PeihuiLin, LiangHan, PeidongHan, YanruWang, ZhengChen, GuangjuJi, MingZheng, NoahWeisleder, Rui-PingXiao, HiroshiTakeshima, JianjieMa, HepingCheng
Journal: Circulation Research (2010)

Rationale: Unrepaired cardiomyocyte membrane injury causes irreplaceable cell loss, leading to myocardial fibrosis and eventually heart failure. However, the cellular and molecular mechanisms of cardiac membrane repair are largely unknown. MG53, a newly identified striated muscle-specific protein, is involved in skeletal muscle membrane repair. But the role of MG53 in the heart has not been determined. Objective: We sought to investigate whether MG53 mediates membrane repair in cardiomyocytes and, if so, the cellular and molecular mechanism underlying MG53-mediated membrane repair in cardiomyocytes. Moreover, we determined possible cardioprotective effect of MG53-mediated membrane repair. Methods and Results: We demonstrated that MG53 is crucial to the emergency membrane repair response in cardiomyocytes and protects the heart from stress-induced loss of cardiomyocytes. Disruption of the sarcolemmal membrane by mechanical, electric, chemical, or metabolic insults caused rapid and robust translocation of M...
Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia
Authors: Tongyuan Xue, Marissa Del Real, Emanuela Marcucci, Candida Toribio, Sonia Maryam Setayesh, Stephen J Forman, David A Horne, Lihua E Budde
Journal: Blood (2019)